Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia

A Prospective, Randomized, Controlled Multicenter Trial of Probiotics and Prebiotics to Improve the Efficacy of Antipsychotics in Patients With Schizophrenia

In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment, gastrointestinal function, and metabolic disorders in schizophrenia patients, through genotype identification, psychopathology, neuropsychology, biochemical evaluation and other methods.

Study Overview

• Status: Recruiting
• Conditions: Schizophrenia
• Intervention / Treatment: Dietary supplement: maltodextrin; Drug: Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables); Dietary supplement: Prebiotics (Combined inulin and maltodextrin tables)

Detailed Description

The study will recruit 210 schizophrenia patients who meet the criteria of DSM-4, and then randomized to 3 groups: control group, probiotics group and prebiotics group for a 14-weeks clinical trail and 12-weeks follow-up period. In addition to probiotics, prebiotic or maltodextrin interventions, in the meantime, all participants will also use one of the prescribed antipsychotics medications. Clinical efficacy and safety assessment will be done at baseline, clinical trail and follow-up period. The specific aims are to evaluate these tips: 1) psychotic syndrome; 2) cognition; 3) Gastrointestinal function; 4) inflammatory and metabolic related markers. Psychotic syndrome will be measured by the Positive and Negative Syndrome Scale. Cognitive function will be assessed by the MATRICS Consensus Cognitive Battery. Gastrointestinal function will be assessed by gastrointestinal symptom assessment scale (GSRS). Biological samples also will be collected, and stored to research Intestinal inflammation, intestinal permeability, intestinal flora and other indicators.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: YingYing Dong, M.D.; Phone Number: 0086-13992808564; Email: 406022725@qq.com

Study Locations

• China
  • Shanxi
    • Xi'an, Shanxi, China, 710061
      • Recruiting
      • First Affiliated Hospital of Xi'an Jiao Tong University
      • Contact: Xiancang Ma, M.D.; Phone Number: 0086-13002951782; Email: maxiancang@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Meet the Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for schizophrenia
• Duration of illness 5 years, Subjects are currently receiving first-line recommended antipsychotic medication
• The total PANSS score ≥60, containing at least three positive or negative items with scores of 3 or more at screening
• Junior high school or above
• Capacity for written informed consent.

Exclusion Criteria:

• Pregnant or lactating women
• Any clinically significant or unstable medical disorder as determined by the investigators, including congestive heart failure, abnormal liver function, renal failure, immunodeficiency diseases, cancer, or gastrointestinal diseases ( inflammatory bowel disease or celiac disease, except functional constipation)
• Subjects had acute or chronic infections or are taking anti-inflammatory drugs and cortisol hormones. Receipt of antibiotic medication within the previous 1 month.
• Other neuropsychiatric disorders (organic diseases of the central nervous system, a mental disorder caused by a physical disease or psychoactive substance, mental retardation).
• Having history of substance dependence or abuse，including alcohol
• BMI is not within the normal range (18.5 to 23.9)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control group; Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks	Dietary supplement: maltodextrin; Maltodextrin tables (oral,daily for 14 weeks)
Experimental: Probiotics group; Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0*10^9 colony forming units, oral, daily for 14 weeks	Drug: Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables); The probiotic compound will consist of tables containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).; Other Names: Probiotic bacteria
Experimental: Prebiotics group; Combined inulin+maltodextrin tables, oral, daily for 14 weeks	Dietary supplement: Prebiotics (Combined inulin and maltodextrin tables); The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Positive and Negative Syndrome Scale (PANSS) Score from week0 to week26	The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The clinical efficacy was evaluated by its score reduction rate, with the total score reduction rate ≥75% as recovery, 50% ~ 74% as significant improvement, 25% ~ 49% as improvement, and <25% as invalid. improvement, significant improvement and recovery add up to apparent effect.	26weeks(week0 to week26)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in MATRICS Consensus Cognitive Battery(MCCB) Score from week1 to week26	Change in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) score from the start of Trial period to the end of the follow-up phase; Cognitive performance is measured by the MATRICS Consensus Cognitive Battery composite score in participants.	week26(week1 to week26 )
Gastrointestinal symptom rating scale (GSRS)	Gastrointestinal function will be assessed during the screening stage，week 4, week 8, week 12, week 14 of treatment stage and once every 4 weeks of follow-up stage through Gastrointestinal symptom rating scale (GSRS); The score reduction of GSRS≥25% was associated with improvement in gastrointestinal function.	week26 (week1 to week26)
Serum inflammatory factors-TH-1	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines --TH-1	week26(week1 to week26)
Serum inflammatory factors-TH-2	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines--TH-2	week26(week1 to week26)
Serum inflammatory factors-TH-17	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines--TH-17	week26(week1 to week26)
Serum inflammatory factors-Interleukin-1	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines--Interleukin-1	week26(week1 to week26)
Serum inflammatory factors-Interleukin-2	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines --Interleukin-2	week26(week1 to week26)
Serum inflammatory factors-Interleukin-6	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines --Interleukin-6	week26(week1 to week26)
Serum inflammatory factors-Interleukin-10	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines --Interleukin-10	week26(week1 to week26)
Serum inflammatory factors-Interleukin-17	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines --Interleukin-17	week26(week1 to week26)
Serum inflammatory factors-TNF-a	Change of intestinal inflammation will be assessed during the the double-blind phase, including serum inflammatory cytokines --TNF-a(tumor necrosis factor-a,interferon).	week26(week1 to week26)
Fecal intestinal flora	The number of lactobacillus and bifidobacterium flora will be assessed; The species and abundance of intestinal flora were identified by 16SrRNA.	week26 (week1 to week26)
Serum intestinal permeability index-FABP2	Change of Serum intestinal permeability index will be assessed during the the double-blind phase- FABP2	week26(week1 to week26)
Serum intestinal permeability index-sCD14	Change of Serum intestinal permeability index will be assessed during the the double-blind phase-sCD14	week26(week1 to week26)
Serum intestinal permeability index-LBP	Change of Serum intestinal permeability index will be assessed during the the double-blind phase-LBP	week26(week1 to week26)

Collaborators and Investigators

• Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Collaborators: Xiangyang Central Hospital; BaoJi Rehabilitation Hospital; WeiNan Psychiatry Hospital; HanZhong Psychiatric Hospital
• Investigators: Study Chair: Xiancang Ma, M.D., First Affiliated Hospital Xi'an Jiaotong University

Study record dates

Study Major Dates

• Study Start (Actual): March 3, 2022
• Primary Completion (Anticipated): December 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: February 13, 2020
• First Submitted That Met QC Criteria: February 27, 2020
• First Posted (Actual): March 2, 2020

Study Record Updates

• Last Update Posted (Actual): April 8, 2022
• Last Update Submitted That Met QC Criteria: April 6, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Schizophrenia; Probiotics
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: XJTU1AF-CRF-2019-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: If necessary, part of the data can be obtained through the project leader.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No